In vivo experiments reported back in 2010 with the commercial agent LipoplatinTM, which had already reached phase II/III clinical studies for non-small-cell lung cancer (NSCLC) [162], HER2/neu negative metastatic breast tumour [163], and advanced gastric tumour, were not successful [164]. Here, ERBB2 is linked to non-small cell lung carcinoma.